HUB & Patient Support Solutions Complement Pre-Commercialization Services
AscellaHealth’s expanded HUB/ Patient Support Services for Life Sciences manufacturers are recognized as the best-in-class outsourced solutions for successful medication access, compliance and persistency and enhanced outcomes.
Re-Think. Re-Consider. Re-Calibrate.
2023 Go-to-Market Strategies for Launching Specialty Drugs, Gene & Cell Therapies
Something for Everyone at Rare Disease Week on Capitol Hill
Rare Disease Week on Capitol Hill, February 28th through March 2nd, 2023.
AscellaHealth Specialty Pharmacy Distribution & Market Access Webinar Highlights
Experts provide in-depth insights on commercialization strategy, distribution models and demonstrating therapeutic value of Rare Disease & Gene/Cell therapies for patients, payers, and providers.
Patient-First Approach: Initial Step in Addressing Nation’s Health Inequities
Removing barriers to reach Health equity.
Optimizing Treatment for Rare Genetic Condition: Cushing’s Syndrome
Cushing’s syndrome, a rare endocrine disorder and FDA approved treatments.
Update on Gene Therapy and Genome-Editing for Rare Diseases
There’s some upbeat news in gene therapy and genome-editing treatments.
Pharmaceutical Companies Turn to AscellaHealth Family of Companies for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services
Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.
Patient Services and Hub Solutions for Life Sciences: Ensuring Specialty Product Access and Market Entry, Optimizing Outcomes for Rare Disease Patients
The rare disease community is gaining attention around the world, shining a light on the challenges and barriers to accessing care.
340B Drug Pricing Program Undermined by Restrictions
In recent years, the 340B Drug Pricing program has experienced discount restrictions.
Navigating JAK Inhibitor Warnings
Janus kinase (JAK) inhibitors help ease joint pain and swelling in patients with rheumatoid arthritis.